Rxsight Inc
RXST
查看詳細走勢圖
10.930USD
-0.530-4.62%
收盤 12/26, 16:00（美東）報價延遲15分鐘
449.02M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-4.62%
5天
-9.14%
1月
-5.12%
6月
-13.73%
今年開始到現在
-68.21%
1年
-68.06%
查看詳細走勢圖
TradingKey Rxsight Inc股票評分
單位: USD 更新時間: 2025-12-26操作建議
Rxsight Inc當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在醫療設備與耗材行業排名72/207位。機構持股佔比非常高，近一個月多位分析師給出公司評級為持有。最高目標價10.00。中期看，股價處於上升通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Rxsight Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
11
分析師
持有
評級
10.000
目標均價
-20.38%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Rxsight Inc亮點
亮點風險
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
業績高增長
公司營業收入穩步增長，連續3年增長185.54%
估值高估
公司最新PE估值-12.47，處於3年歷史高位
機構減倉
最新機構持股38.67M股，環比減少19.32%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉，最新持倉3.57K股
Rxsight Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Rxsight Inc簡介
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
公司代碼RXST
公司Rxsight Inc
CEOKurtz (Ron M)
網址https://www.rxsight.com/
常見問題
Rxsight Inc(RXST)的當前股價是多少？
Rxsight Inc(RXST)的當前股價是 10.930。
Rxsight Inc 的股票代碼是什麼？
Rxsight Inc的股票代碼是RXST。
Rxsight Inc股票的52週最高點是多少？
Rxsight Inc股票的52週最高點是37.130。
Rxsight Inc股票的52週最低點是多少？
Rxsight Inc股票的52週最低點是6.320。
Rxsight Inc的市值是多少？
Rxsight Inc的市值是449.02M。
Rxsight Inc的淨利潤是多少？
Rxsight Inc的淨利潤為-27.45M。
現在Rxsight Inc(RXST)的股票是買入、持有還是賣出？
根據分析師評級，Rxsight Inc(RXST)的總體評級為持有，目標價格為10.000。
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是多少
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是-0.877。
相關品種
+1.30%
+0.29%
+0.03%
+0.11%
-0.49%
-0.05%
-0.13%
-0.75%
+0.67%
+0.59%
+1.91%
+0.59%
+0.34%
+0.09%
+0.04%
+0.64%
+0.26%
+0.05%
+0.26%
+0.67%
